Strong sales growth and key milestones achieved
First quarter 2022 (1 Jan - 31 Mar)
• Net sales amounted to
• All business areas showed underlying organic growth. Adjusted for currency effects; Thoracic 35 percent, Abdominal 21 percent and Services 53 percent. Acquired growth was 15 percent.
• Three XPS-machines were sold during the quarter.
• Gross margin on disposables improved to 79 percent (76). Total gross margin was 70 percent (74) affected by productmix.
• Operating profit before depreciation and amortization (EBITDA) amounted to
• Operating profit (EBIT) amounted to
• Net profit amounted to
• Cash flow from operating activities amounted to
Significant events during the quarter
• XVIVO’s heart technology used in the world’s first ever successful heart xenotransplant (pig to human)
•
• XVIVO obtains its first certificate under
• Regulatory approval in
CEO-comment
“It was an encouraging start to the year with a new sales record for a single quarter and significant interest in our XPS technology for lungs, which resulted in three sold XPS machines. Due to strong sales and margin improvements in both Thoracic and Abdominal, profitability in the quarter was good. Furthermore, the quarter delivered several key milestones including the xenotransplantation of a heart from a pig to a human, which had extensive media coverage, and the FDA clearance of
© Modular Finance, source